- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04192500
Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years
September 20, 2022 updated by: Osivax
A Phase 2a, Single Center, Randomized, Double-blind, Controlled Study to Evaluate the Immunogenicity and the Safety of One Dose of OVX836 Influenza Vaccine at Two Dose Levels (90 µg and 180 μg), in Comparison to Influvac TetraTM, Quadrivalent Seasonal Influenza Sub-unit Vaccine, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years
This Phase 2a clinical study is designed to evaluate the immunogenicity and the safety of one dose of OVX836 influenza vaccine administered IM, confirm the dose level and regimen, and expand immunogenicity and safety data to adults through age 65.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 2a, randomised, double-blind study in 300 adults to compare the safety and immunogenicity of OVX836 to QIV (Influvac TetraTM).
One dose of OVX836 at two dose levels will be administered intramuscularly, in comparison to Influvac TetraTM, quadrivalent seasonal influenza sub-unit vaccine in healthy subjects aged 18-65 years.
Study Type
Interventional
Enrollment (Actual)
300
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ghent, Belgium, 9000
- Centre for Vaccinology (CEVAC)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent.
- Healthy male or female subjects, as determined by medical history and medical examination.
- Between the ages of 18 and 65 years, inclusive.
- Reliable and willing to make themselves available for the duration of the study, and willing and able to follow study procedures.
Exclusion Criteria:
- Subject with a body mass index (BMI) ≥35 kg/m² on the day of vaccination.
- Previous influenza vaccination within 6 months before the day of vaccination, or planned to receive during the study duration.
- Any known or suspected immunodeficient conditions.
- Past or current history of significant autoimmune diseases, as judged by the Investigator.
- Current history of significant uncontrolled medical illness such as diabetes, hypertension, heart, renal or hepatic diseases, as judged by the Investigator.
- Female subjects: pregnant, breast-feeding or of childbearing potential without appropriate contraceptive methods in place for 2 months before enrolment, or with positive pregnancy test on the day of vaccination. Appropriate contraceptive methods are defined by the Clinical Trial Facilitation Group [CTFG] as follow: "Contraceptive methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include: combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable intrauterine device, intrauterine hormone-releasing system), bilateral tubal occlusion, vasectomized partner and/or sexual abstinence (refraining from heterosexual intercourse)."
- Having received another vaccination within 3 months prior to the day of study vaccination for live attenuated vaccines, or within 1 month prior to the day of study vaccination for inactivated vaccines.
- Planning to receive other vaccines during the first 28 days following the study vaccine administration.
- Administration of any investigational or non-registered drug or vaccine within 3 months prior to the administration of study vaccines, or planned administration of any such product during the whole study period.
- History of receiving blood, blood components or immunoglobulins within 3 months prior to the day of vaccination, or planned to receive such product during the whole study period.
- Presence of an acute febrile illness on the day of vaccination (oral temperature >38.0°C, temporary exclusion criterion).
- Past or current history of any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome.
- Behavioral or cognitive impairment, or psychiatric disease that, in the opinion of the Investigator, may interfere with the subject's ability to participate in the study.
- Past (stopped less than 6 months before enrolment) or current history of alcohol or drug abuse, or current smoking habit above 10 cigarettes per day.
- Treatment that can affect immune response such as systemic or high dose inhaled corticosteroids (>800 μg/day beclomethasone or equivalent; occasional inhaled corticosteroids for asthma therapy are allowed), radiation treatment, cytotoxic drugs, or current or recent (within 30 days before study entry) chronic or prolonged (>10 days) use of systemic non-steroidal anti-inflammatory drugs, interferon, immunomodulators, allergy shots, as judged by the Investigator.
- Subjects with known or suspected anemia.
- Recent blood or platelets donation (less than 3 months before enrolment). History of plasma donation is authorized.
- History of severe allergic reactions and/or anaphylaxis, or serious adverse reactions to vaccines or allergy to kanamycin, or to any component that may be present in the comparator vaccine, as traces such as eggs (ovalbumin, chicken proteins), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80, or gentamicin.
- Any contraindication to intramuscular administration, as judged by the Investigator.
- Individuals with history of any illness that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.
- Technical difficulties in the use of an e-diary.
- Sponsor employees or Investigator site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OVX836 - 90µg dose
Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus.
One single administration intramuscularly of a 90µg dose on Day 1.
|
One single administration intramuscularly at Day 1.
|
Experimental: OVX836 - 180µg dose
Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus.
One single administration intramuscularly of a 180µg dose on Day 1.
|
One single administration intramuscularly at Day 1.
|
Active Comparator: Quadrivalent seasonal influenza vaccine (Influvac TetraTM)
Licensed quadrivalent seasonal influenza subunit vaccine for season 2019-2020.
One full dose to be administered at Day 1
|
One single administration intramuscularly at Day 1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
NP-specific IFNγ T-cell increase measured by ELISPOT at Day 8 versus pre-injection baseline (Day 1) in the pooled age strata
Time Frame: at Day 8 versus pre-injection baseline (Day 1)
|
at Day 8 versus pre-injection baseline (Day 1)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects reporting solicited local (Injection site redness, Injection site swelling, Injection site pain) and systemic symptoms (Fatigue, Headache, Arthralgia, Malaise, Myalgia, Fever) using an electronic Diary
Time Frame: during 7 days after vaccine administration
|
during 7 days after vaccine administration
|
Proportion of subjects reporting unsolicited Adverse Events
Time Frame: during 28 days after vaccine administration
|
during 28 days after vaccine administration
|
Proportion of subjects with Influenza-Like-Illness cases associated with laboratory-confirmed influenza
Time Frame: during the whole study duration, 180 days
|
during the whole study duration, 180 days
|
Severity scores of Influenza-Like-Illness cases (as per Flu-PRO® questionnaire)
Time Frame: during the whole study duration, 180 days
|
during the whole study duration, 180 days
|
Proportion of subjects reporting Serious Adverse Events
Time Frame: during the whole study duration, 180 days
|
during the whole study duration, 180 days
|
NP-specific IFNγ T-cell activity measured by ELISPOT in the pooled age strata and by age stratum (18-49 years; 50-65 years)
Time Frame: at Day 8, Day 29 and Day 180 versus pre-injection baseline (Day 1)
|
at Day 8, Day 29 and Day 180 versus pre-injection baseline (Day 1)
|
NP T-cell phenotype and functionality by flow cytometry in the pooled age strata and by age stratum (18-49 years; 50-65 years)
Time Frame: at pre-injection baseline (Day 1), Day 8, Day 29 and Day 180
|
at pre-injection baseline (Day 1), Day 8, Day 29 and Day 180
|
Anti-NP Immunoglobulin G (IgG) titers by ELISA at each time point in the pooled age strata and by age stratum (18-49 years; 50-65 years)
Time Frame: at pre-injection baseline (Day 1), Day 8, Day 29 and Day 180
|
at pre-injection baseline (Day 1), Day 8, Day 29 and Day 180
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 11, 2019
Primary Completion (Actual)
September 7, 2020
Study Completion (Actual)
September 7, 2020
Study Registration Dates
First Submitted
December 3, 2019
First Submitted That Met QC Criteria
December 6, 2019
First Posted (Actual)
December 10, 2019
Study Record Updates
Last Update Posted (Actual)
September 22, 2022
Last Update Submitted That Met QC Criteria
September 20, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OVX836-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on OVX836
-
OsivaxAepodiaCompleted
-
OsivaxHôpital Cochin; ClinactNot yet recruiting
-
OsivaxCenter for vaccinology (CEVAC), University of GhentCompleted
-
OsivaxNovotech (Australia) Pty Limited; Harmony Clinical Research; Northern Beaches...Completed
-
OsivaxNovotech (Australia) Pty Limited; Mater Misericordiae LimitedCompleted